Lyme Science Blog

by Daniel J. Cameron, MD MPH Persistent infection of Borrelia burgdorferi (Bb) has been proven experimentally in Peromyscus mice, laboratory mice, rats, hamsters, gerbils, guinea pigs, dogs and non-human primates. [1-8] Some researchers and clinicians argue, the existence of a persistent Bb infection explains why some Lyme disease patients remain sick even after treatment. According to one study, as many […]

The Infectious Disease Society of America (IDSA) has long insisted that a maximum antibiotic course of 21 days is sufficient to eradicate the Lyme bacterium, while the International Lyme and Associated Diseases Society (ILADS) recommends a longer course of therapy with duration dependent on response to therapy. [1] So, what treatment approach are physicians adopting in their

Lyme in the Limelight, published by Hamodia newspaper, features interviews with veterans in the field including researchers, physicians and advocacy leaders. As a representative of the Infectious Disease Society of America (IDSA) and co-author of the practice guidelines for the treatment of Lyme disease, Dr. Eugene Shapiro gives his perspective on an illness he believes is easy

Dr. Daniel Cameron & Associates, located in the Hudson Valley New York area, is uniquely positioned in a region where Lyme disease is endemic, enabling the practice to participate in much-needed clinical research projects, including the validation of newly developed Lyme disease tests. Since 1987, Dr. Cameron has been evaluating and treating thousands of individuals with tick-borne

Dr. Neil Spector, one of the nation’s top cancer researchers and oncologists, has become a powerful advocate for Lyme disease patients. In his memoir, Gone in a Heartbeat: A Physician’s Search for True Healing, Dr. Spector chronicles his battle with debilitating and at times, life threatening cardiac problems due to undiagnosed Lyme carditis. Despite his standing within the medical community, physicians and

The study describes a significant problem with under-reporting (∼196 unreported cases per year) based on data from BlueCross BlueShield of Tennessee (BCBST), and the Center for Environmental and Communicable Diseases. The paper proposed using medically diagnosed cases from a Tennessee-based Managed Care Organization (MCO) to help bridge gaps in the surveillance system. (See table below.) In

by Daniel J. Cameron, MD MPH Researchers from Duke University Health System in North Carolina reviewed the medical records of 1,621 patients, who had a clinical history consistent with Lyme disease and sought treatment at the facility between 2005 and 2010. [1] The authors, who were examining the predictive value of Lyme disease tests, discuss their

 “The increases in the geographic range and population sizes of several tick species over the previous few decades in the northern hemisphere have resulted in dramatic increases in the incidence of tick-borne diseases such as tick-borne encephalitis, Lyme disease, Babesiosis, Anaplasmosis, and human granulocytic Ehrlichiosis,” says Camilo E. Khatchikian, a postdoctoral researcher in Penn’s Department

“Minds are like parachutes. They only function when open.” This particular quote by Thomas Dewar came to mind after reading an article, Chronic Lyme Disease (1) in the June issue of Infectious Disease Clinics of North America. In it, the author writes, “the scientific community has largely rejected chronic, treatment-refractory Borrelia burgdorferi infection.” This is based on “the failure

Research studies examining impaired or heightened sense of smell have been focused primarily on patients suffering from neurological disorders, like Alzheimer’s and Parkinson’s disease. Only recently, have researchers begun to investigate the connection between olfactory disorders and autoimmune diseases.  And, while there have been many anecdotal reports from Lyme disease patients complaining about their sensitivity